Pfizer is paying $44 million to settle a Chantix lawsuit. See who could get money
Pharmaceutical company Pfizer has agreed to a $44 million class action settlement over its oral prescription medication Chantix. The drug which was first approved by the FDA in May 2006 and was used to help smokers quit until it was taken off the market in 2021. The lawsuit claims that prescription medication was contaminated with high levels of a certain nitrosamine, a known carcinogen that may…
Pharmaceutical giant Pfizer has settled a class action lawsuit over its smoking cessation drug Chantix for $44 million. The drug, which was first approved by the FDA in 2006 and taken off the market in 2021, was accused of being contaminated with high levels of a known carcinogen called nitrosamine, potentially increasing the risk of cancer.
The lawsuit also alleged that Pfizer failed to follow current manufacturing practices and violated consumer protection laws. However, Pfizer maintains it did nothing wrong. Consumers who purchased the drug between September 29, 2015 and September 17, 2021 in the US and its territories are eligible for a payout, provided they can provide proof of their purchase.
The settlement will be distributed on a pro rata basis, with a maximum of 20% of the available fund per consumer. The final payout amount will depend on the outcome of the final approval hearing on October 13, 2026. The drug recall and subsequent legal action come after over 2,700 lawsuits were filed over claims that Chantix led to mental health issues and a murder-suicide case was linked to the drug.
Written by urgent.news from Fast Company's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
